Home > Boards > US Listed > Biotechs > Eloxx Pharmaceuticals Inc. (ELOX)

On analyst had recently mentioned in an article

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It’s ERSG Library In Two Leading Journals GlobeNewswire Inc. - 10/27/2020 7:30:10 AM
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference GlobeNewswire Inc. - 10/22/2020 8:57:31 AM
Eloxx Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020 GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant GlobeNewswire Inc. - 9/14/2020 10:06:20 AM
Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Confer... GlobeNewswire Inc. - 8/26/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2020 7:55:55 AM
Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 P... GlobeNewswire Inc. - 8/12/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 8:16:56 AM
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update GlobeNewswire Inc. - 8/6/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 7:51:30 AM
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis GlobeNewswire Inc. - 8/4/2020 7:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:05 PM
Eloxx Pharmaceuticals to Present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13th, 2020 GlobeNewswire Inc. - 7/28/2020 12:33:50 PM
Eloxx Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020 GlobeNewswire Inc. - 7/21/2020 2:17:29 PM
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics GlobeNewswire Inc. - 7/15/2020 1:08:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2020 4:47:30 PM
Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily ... GlobeNewswire Inc. - 6/17/2020 4:01:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/26/2020 3:04:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:12:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:25 PM
investora2z   Thursday, 11/14/13 10:52:16 AM
Re: None
Post # of 773 
On analyst had recently mentioned in an article on seekingalpha that Senesco stock has suffered over the past year 'for no instantly recognizable reason'. He had concluded by saying that the market currently values the company at a discount to its peers, despite consistently positive trial data. Regarding the technology being developed by Senesco, he had said 'the science behind SNS01-T is a revolutionary, cutting-edge approach to cancer treatment, and if proven effective could be applied to a range of other diseases. Upcoming catalysts including cohort three and cohort four results could reverse investor sentiment, and in turn, initiate a market revaluation of Senesco.' The company will announce the results of the trials soon. It had announced that it will make two presentations on SNS01-T for blood-borne cancer care at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 7-10th in New Orleans. The management stated that the company will provide an update on the current results of the trial, and also make an oral presentation of new results with SNS01T in non-clinical studies. Though the FDA approval etc. may take a couple of years, the preliminary results of the trials have been encouraging. If the upcoming results are as encouraging on tolerability & efficacy, then the stock may start an uptrend. It is important to note that the main purpose of the trials so far has been to test the safety and tolerability of the drug, and exploring whether SNS01T is an effective treatment for multiple myeloma, mantle cell lymphoma and diffuse large B cell lymphoma is the second objective. It is obviously good to invest in a development stage company before the stock takes of due to some important event. Many analysts are already positive on the stock, based on expected positive outcome of the trials.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences